In non-APL AML Schuch et al. [45] demonstrated that VEGF administration resulted in enhanced tumor growth and vascularization whereas treatment with a VEGF antagonist soluble NRP-1 inhibited tumor angiogenesis and growth in a chloroma mouse model. This evidence concerns the gene VEGFA and acute promyelocytic leukemia.